KOL Perspectives: Update on Novel Candidates in Development for Lupus
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› The briefing includes analysis of KOL opinion on the following topic areas:
›Atacicept’s efficacy data in SLE
›Atacicept’s flare data in SLE
›Patients most suitable for atacicept treatment
›Targeting the IgE pathway in lupus
›Omalizumab’sefficacy data in SLE
›Omalizumab’ssafety data in SLE
›Lupuzor’s Phase III efficacy data
›Impact of lupuzor’s Phase III data on existing opinion of lupuzor
›Lupuzor’s Phase III safety data in SLE
›Anticipated future use of lupuzor in clinical practice
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our lupus key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– Five Europe-based & fuve US-based
– Interviews performed in Q2 2018
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Most KOLs had a positive opinion of atacicept’s efficacy in SLE despite failure to achieve its primary endpoint of SRI-4 in the ITT population
KOL opinions were divided in terms of targeting the IgE pathway in lupus, with some unaware of any scientific rationale behind it
Most KOLs were disappointed by lupuzor’s Phase III efficacy data but were not surprised by the high placebo response rate observed in the trial
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on "Novel Candidates in Development for Lupus"
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Novartis
Roche
Genentech
ImmuPharma
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.